Fulgent Genetics, Inc.
For the period ended Mar 31, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 1, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit No. | Exhibit Title | Filed with this Form 10-Q | Form | Form No. | Date Filed |
| 2.1§ | Purchase and Sale Agreement, dated December 20, 2025, by and among Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Dermatopathology Experts, LLC, Fulgent Therapeutics LLC, and Inform Diagnostics, Inc. | 8-K | 001-37894 | 12/22/2025 | |
| 2.2§ | Asset Purchase Agreement, dated December 20, 2025, by and among Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting, LLC, Fulgent Therapeutics, LLC, and Inform Diagnostics, Inc. | 8-K | 001-37894 | 12/22/2025 | |
| 3.1 | Certificate of Incorporation of the registrant, as amended. | 10-Q | 001-37894 | 8/14/2017 | |
| 3.1.1 | Certificate of Amendment to Certificate of Incorporation of the registrant, dated August 2, 2016. | 10-Q | 001-37894 | 8/14/2017 | |
| 3.1.2 | Certificate of Amendment to Certificate of Incorporation of the registrant, dated May 17, 2017. | 10-Q | 001-37894 | 8/14/2017 | |
| 3.2 | Amended and Restated Bylaws of the registrant. | 10-Q | 001-37894 | 8/4/2023 | |
| 10.1+ | Commercial Lease Agreement, dated July 21, 2015, by and between BH Georgia Properties, LLC and Bakotic Pathology Associates L.L.C., as amended. | X | |||
| 10.2 | Assignment and Assumption of Lease, dated March 16, 2026, by and between Bakotic Pathology Associates, L.L.C. and Inform Diagnostics, Inc. | X | |||
| 31.1^ | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2^ | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | X | |||
^ Filed herewith.
- Furnished herewith.
§ Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted exhibits or schedules upon request by the Securities and Exchange Commission; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any exhibits or schedules so furnished.
- Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.